CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark bought 132 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were acquired at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).
CSL Stock Performance
The stock has a market capitalization of $77.43 billion, a PE ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.
CSL Increases Dividend
The business also recently declared a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be given a dividend of $2.073 per share. The ex-dividend date of this dividend is Sunday, March 9th. This is a boost from CSL’s previous Interim dividend of $1.83. This represents a dividend yield of 0.81%. CSL’s dividend payout ratio (DPR) is currently 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
- Five stocks we like better than CSL
- 3 Small Caps With Big Return Potential
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Investing in the High PE Growth Stocks
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- How to Invest in the FAANG Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
